Garphi Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-07-2024
- Paid Up Capital ₹ 1.00 Cr
as on 09-07-2024
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -23.16%
(FY 2022)
- Profit -67.53%
(FY 2022)
- Ebitda -63.95%
(FY 2022)
- Net Worth 17.33%
(FY 2022)
- Total Assets -15.58%
(FY 2022)
About Garphi Biosciences
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkat Bundla, Padmaja Bundla, and Nikita Bundla serve as directors at the Company.
- CIN/LLPIN
U73100TG2008PTC058678
- Company No.
058678
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Apr 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Garphi Biosciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkat Bundla  | Managing Director | 15-Apr-2008 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Padmaja Bundla | Director | 15-Apr-2008 | Current |
| Nikita Bundla | Additional Director | 02-Apr-2020 | Current |
Financial Performance of Garphi Biosciences.
Garphi Biosciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 23.16% decrease. The company also saw a substantial fall in profitability, with a 67.53% decrease in profit. The company's net worth Soared by an impressive increase of 17.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Garphi Biosciences?
Unlock access to Garphi Biosciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Biodoz Therapeutics Private LimitedActive 11 years 11 monthsVenkat Bundla and Padmaja Bundla are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Garphi Biosciences?
Unlock and access historical data on people associated with Garphi Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Garphi Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Garphi Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
